Multimorbidity, polypharmacy, and COVID-19 infection within the UK Biobank cohort.
Ross McQueenieHamish M E FosterBhautesh D JaniVittal Srinivasa KatikireddiNaveed SattarJill P PellFrederick K HoClaire L NiedzwiedzClaire E HastieJana Jane AndersonPatrick B MarkMichael K SullivanCatherine A O'DonnellFrances S MairBarbara I NichollPublished in: PloS one (2020)
Increasing multimorbidity, especially cardiometabolic multimorbidity, and polypharmacy are associated with a higher risk of developing COVID-19. Those with multimorbidity and additional factors, such as non-white ethnicity, are at heightened risk of COVID-19.
Keyphrases